[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580230":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":48,"responsibleParty":73,"collaborators":42,"id":75,"slug":42,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":42,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Children's Mercy Hospital Kansas City","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequential progesterone supplementation","ACTIVE_COMPARATOR","Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle.",[13],"Drug: Micronized progesterone 200 MG",{"label":15,"type":10,"description":16,"interventionNames":17},"Continuous progesterone supplementation:","Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.",[18],"Drug: Micronized Progesterone 100 MG",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Micronized progesterone 200 MG","Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle",[9],[26],"Sequential",{"type":21,"name":28,"description":16,"armGroupLabels":29,"otherNames":30},"Micronized Progesterone 100 MG",[15],[31],"Continuous",[33],{"name":34,"affiliation":35,"role":36},"Tazim Dowlut-McElroy, M.D., M.S.","Children's Mercy Kansas City","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Allie Ranallo","CONTACT","+1-816-394-7534",null,"alranallo@cmh.edu",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Andrea Manlove","+1-816-731-7326","almanlove@cmh.edu",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Children's Mercy Hospital","RECRUITING","Kansas City","Missouri","64108","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-94.57857,39.09973,{"lat":61,"lon":60},[64,66,67,68,71],{"name":39,"role":40,"phone":65,"phoneExt":42,"email":43},"816-394-2574",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},{"name":34,"role":36,"phone":42,"phoneExt":42,"email":42},{"name":69,"role":70,"phone":42,"phoneExt":42,"email":42},"Madeline Ross, M.D.","SUB_INVESTIGATOR",{"name":72,"role":70,"phone":42,"phoneExt":42,"email":42},"Joseph Cernich, M.D.",{"type":74,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100580230",false,"NCT06834594","Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome","Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome: A Non-randomized Prospective Trial (The BOOST Study)","BOOST","Inclusion Criteria:\n\n* Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.\n* Prescribed adult dosing\\* of transdermal or oral estradiol for estrogen replacement therapy.\n\n  \\*Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg\u002Fday of transdermal estradiol, or (i.e. 50-200μg\u002Fday of transdermal estradiol or 2-4mg\u002Fday oral estradiol).\n* Have achieved menarche.\n\nExclusion Criteria:\n\n* Disclosure of sexual activity and desire for contraception.\n* Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.\n* Having received depot medroxyprogesterone within one year prior to study recruitment.\n* Non-English or non-Spanish speaking.","FEMALE","12 Years","20 Years",{"count":86,"type":87},40,"ESTIMATED","INTERVENTIONAL",[90],"PHASE4","This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).",[93,94],"Turner Syndrome","Primary Ovarian Insufficiency (Poi)",[96,97,98],"Turner syndrome","Primary ovarian insufficiency","Hormone replacement therapy","2025-08-27",{"date":101,"type":102},"2025-09-04","ACTUAL",{"date":104,"type":102},"2025-07-31",{"date":106,"type":87},"2026-07-31",{"name":5,"class":6},1]